RxDoctor Payments Data

Mary Bailey, MD

Neurology · New Haven, CTNPI 1558543686

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $507,267 of the $629,501 with a category attached, or 80.6%. 17 manufacturers reported payments, led by Biogen at 25.1% of the total. Among neurology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$629,501in general payments, 2019–2025

Across 464 payments — averaging $1356.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$158K
  • TG Therapeutics, Inc.$140K
  • EMD Serono, Inc.$87K
  • Genentech USA, Inc.$79K
  • Novartis$52K
  • Bristol Myers Squibb$39K
  • plus $74K from 11 others

What the payments were for

  • Consulting fees$82,32913%
  • Speaking & faculty fees$507,26781%
  • Travel & lodging$28,8445%
  • Food & beverage$10,8882%
  • Education$1730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$629,501 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$24,007
Medicare patients
75
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab49$499,088
AubagioTeriflunomide30$310,677
VumerityDiroximel Fumarate30$261,682
Avonex (4 Pack)Interferon Beta-1a14$147,625
TecfideraDimethyl Fumarate11$107,879
CopaxoneGlatiramer Acetate14$80,338
Dalfampridine ErDalfampridine55$15,325
Baclofen134$4,228
Gabapentin92$2,123
Modafinil24$1,854
Tizanidine Hcl49$1,567
Ropinirole Hcl16$549
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine27$544
AmantadineAmantadine Hcl17$332
Clonazepam24$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Avonex (4 Pack), Tecfidera$157,852$517,18655 claims
SanofiAubagio$34,733$310,67730 claims
Teva Pharmaceuticals USA, Inc.Copaxone$12$80,33814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.

Other neurology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →